OPM Biosciences
奥浦迈
OPM Biosciences (奥浦迈) is a Shanghai-based biotech company specializing in cell culture media and biological CDMO services, per a Dalton Venture piece from October 2025 . Its chairman and general manager is Xiao Zhihua, who represented the company at the "Wanwu Capital" bio-manufacturing conference that month .
The company has positioned itself as an industrial anchor in China's bio-manufacturing push. In October 2025, it co-launched Shanghai's first bio-manufacturing industry fund with Dalton Venture, a "C+VC" dual-wheel vehicle pairing OPM's industrial capabilities with the investor's early-stage life-science and synthetic-biology track record . The fund targets a RMB 1 billion scale and has been selected as a sub-fund under Shanghai's pilot-industry母基金 . OPM also joined the inaugural "Bio-Manufacturing Industry Value Partners" consortium alongside Dalton Venture, Novo Holdings, Meihua Bio, and research institutions including East China University of Science and Technology .
The entity card provides no additional descriptive detail beyond the company name .
AI-generated — may contain errors, please verify.
Coverage
"NewPro" Raises Tens of Millions of RMB in Pre-A Round; Linear Capital Led Angel Round | Linear Portfolio
Focused on the bio-manufacturing of scarce functional proteins found in nature.
NewPro Closes Tens of Millions of RMB in Pre-A Funding Led by Dalton Venture and SSCI Leading Fund, Achieves FDA Self-GRAS Certification for Self-Developed Lactoferrin | Dalton Venture News
Recently, **NewPro Bioworks (Shanghai Xinyicui Biotechnology Co., Ltd.) announced the completion of a Pre-A funding round worth tens of millions of RMB**. This round was jointly led by **SSCI Leading Fund and Aochuang Pioneer Fund — the latter established by Dalton Venture in partnership with listed industry player OPM Biosciences, making it the first bio-manufacturing industry CVC fund in the Yangtze River Delta region**. Meanwhile, the company's self-developed precision-fermented lactoferrin product
Racing to Compete in the Trillion-Dollar Blue Ocean of Bio-Manufacturing, Heart Capital's Bio-Manufacturing Fund Injects Strong Patient Capital into the Industry
Dalton Venture launched Shanghai's first bio-manufacturing industry fund, injecting strong patient capital into the sector.
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Wanwu Capital's Bio-Manufacturing Industry Partners Conference Convenes in Shanghai! Shanghai's First Bio-Manufacturing Industry Fund Launches, Partners Discuss the Golden Decade
On the afternoon of October 23, 2025, the "Sheng Yan Wan Wu | Bio-Manufacturing Industry Value Partners Conference," co-hosted by Dalton Venture and OPM Biosciences [688293], was held in Shanghai. Centered on the theme "Sheng Yan Wan Wu" (Life Begets All Things), the conference brought together representatives from government agencies, scholars from research institutes, industry-leading entrepreneurs, fund investors, and ecosystem partners to explore cutting-edge trends in bio-manufacturing and pathways for industrial collaboration.
Dalton Venture's Sun Qi: Unlocking a New Era of Industrial Biotechnology with the Power of "Life Derives All Things," Embracing China's Golden Decade of Biomanufacturing | Dalton Insights
Bio-manufacturing: The "Next Decade" of the Global Industrial Landscape
